Reports
Sale
Global Human Insulin Market Price, Share, Growth, Analysis, Forecast: By Product: Drugs, Delivery Device; By Type: Biosimilars, Delivery Device; By Brand: HI Analogs and Biosimilars, HI Biologics; By Delivery Device: Pens, Syringes, Pen Needles, Others; By Application; By Distribution Channel; Regional Analysis; Supplier Landscape; 2023-2031
Global Human Insulin Market Outlook
The global human insulin market value was USD 20.2 billion in 2022, driven by the rising prevalence of diabetes across the globe. The global human insulin market share is anticipated to grow at a CAGR of 3.4% during the forecast period of 2023-2031 to achieve a value of USD 27.3 billion by 2031.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Incidence of Diabetes in North America to Aid the Market Growth of Human Insulin
The market for human insulin is expected to be driven by the growing demand from the North America region over the forecast period. This could be attributed to the rising incidence of diabetes and the increasing geriatric population, which are majorly contributing to the rising demand for human insulin in the region. On the basis of revenue, many countries in Europe like Germany, France, and Italy are predicted to contribute considerably to the growth of the human insulin industry over the forecast period. Meanwhile, the Asia Pacific region is expected to be a favourable market for human insulin over the forecast period. This could be ascribed to the growing research and development activities undertaken by various organisations and rising government initiatives in the region.
Human Insulin: Market Segmentation
Human insulin is referred to the synthetic insulin, which is grown in the laboratory and simulates the insulin in humans. The function of insulin is to regulate fat and carbohydrate metabolism in the body. It was developed through the 1960s and 1970s and finally approved for pharmaceutical use in 1982.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
On the basis of product type, the market is divided into:
- Drugs
- Delivery Device
Based on type, the industry can be segmented into:
- Insulin Analogs and Biosimilars
- Delivery Device
Insulin analogs and biosimilars is further divided on the basis of types into long acting, rapid acting, and pre-mixed, whereas delivery device is divided into intermediate-acting, short-acting, pre-mixed.
By brand, the industry is categorised into:
- NovoRapid/Novolog
- Humalog
- Insuman
- Humulin
- Lantus
- Actrapid, Insulatard, and Mixtard
- Others
On the basis of delivery service, the industry is segregated into:
- Pens
- Syringes
- Pen Needles
- Others
Based on applications, the industry is divided into:
- Type 1
- Type 2
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Investments in R&D Activities to Aid the Market Growth of Human Insulin
The market for human insulin is driven by the rising cases of diabetes and obesity across the globe, which are the resultants of changing lifestyles and unhealthy consumption of sugar in various food and beverages. In addition, the rising investments in research and development activities by several organisations have led to an advanced and easier way of injecting insulin, which is also boosting the market growth of human insulin. Moreover, the introduction of the safety pen devices and pen needles for effective delivery of insulin is propelling the global market forward. Further, growing awareness of diabetes is expected to bolster the demand in the human insulin industry.
Key Industry Players in the Global Human Insulin Market
The report gives a detailed analysis of the following key players in the global human insulin market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Novo Nordisk A/S
- Biocon Limited
- Sanofi S.A.
- Pfizer Inc.
- Eli Lilly and Company
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2021 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Type |
|
| Breakup by Brand |
|
| Breakup by Delivery Device |
|
| Breakup by Application |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Diabetes Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Diabetes Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Diabetes Epidemiology (2016-2031)
5.3 Europe Diabetes Epidemiology (2016-2031)
5.4 Asia-Pacific Diabetes Epidemiology (2016-2031)
5.5 Latin America Diabetes Epidemiology (2016-2031)
5.6 Middle East & Africa Diabetes Epidemiology (2016-2031)
6 Global Human Insulin Market Overview
6.1 Global Human Insulin Market Historical Value (2016-2022)
6.2 Global Human Insulin Market Forecast Value (2023-2031)
7 Global Human Insulin Market Landscape
7.1 Global Human Insulin Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Human Insulin Product Landscape
7.2.1 Analysis by Product Type
7.2.2 Analysis by Distribution Channel
7.2.3 Analysis by Applications
8 Human Insulin Market Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Human Insulin Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Human Insulin Market Segmentation
11.1 Global Human Insulin Market by Product
11.1.1 Market Overview
11.1.2 Drugs
11.1.3 Delivery Device
11.2 Global Human Insulin Market by Type
11.2.1 Market Overview
11.2.2 Biosimilars
11.2.2.1 Long Acting
11.2.2.2 Rapid Acting
11.2.2.3 Pre-Mixed
11.2.3 Delivery Device
11.2.3.1 Intermediate-Acting
11.2.3.2 Short Acting
11.2.3.3 Pre-Mixed
11.3 Global Human Insulin Market by Brand
11.3.1 Market Overview
11.3.2 HI Analogs and Biosimilars
11.3.2.1 NovoRapid/Novolog
11.3.2.2 Lantus
11.3.2.3 Humalog
11.3.2.4 Other Brands
11.3.3 HI Biologics
11.3.3.1 Insuman
11.3.3.2 Humulin
11.3.3.3 Actrapid, Insulatard, and Mixtard
11.3.3.4 Others Brands
11.4 Global Human Insulin Market by Delivery Device
11.4.1 Market Overview
11.4.2 Pens
11.4.2.1 Disposable Pens
11.4.2.2 Reusable Pens
11.4.3 Syringes
11.4.4 Pen Needles
11.4.4.1 Standard Pen Needles
11.4.4.2 Safety Pen Needles
11.4.5 Others
11.5 Global Human Insulin Market by Application
11.5.1 Market Overview
11.5.1.1 Type I Diabetes
11.5.1.2 Type II Diabetes
11.6 Global Human Insulin Market by Distribution Channel
11.6.1 Market Overview
11.6.1.1 Hospital Pharmacy
11.6.1.2 Retail Pharmacy
11.6.1.3 Others
11.7 Global Human Insulin Market by Region
11.7.1 Market Overview
11.7.2 North America
11.7.3 Europe
11.7.4 Asia Pacific
11.7.5 Latin America
11.7.6 Middle East and Africa
12 North America Human Insulin Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Human Insulin Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Human Insulin Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Human Insulin Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Human Insulin Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Regulatory Framework
22.1 Regulatory Overview
22.1.1 US FDA
22.1.2 EU EMA
22.1.3 INDIA CDSCO
22.1.4 JAPAN PMDA
22.1.5 Others
23 Supplier Landscape
23.1 Nova Nordisk A/S
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Biocon Limited
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Sanofi S.A.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Pfizer Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Eli Lilly and Company
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Boehringer Ingelheim International GmbH
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Tonghua Dongbao Pharmaceutical Co. Ltd.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Wockhardt
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Julphar (Gulf Pharmaceutical Industries)
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 The United Laboratories International Holdings Limited
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Ypsomed AG
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Biodel Inc.
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
24 Global Human Insulin Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
Human insulin was valued at USD 20.2 million in 2022.
The market is expected to grow at a CAGR of 3.4% from 2023 to 2031 to reach USD a value of USD 27.3 billion by 2031.
The industry is primarily being driven by the growing incidences of health issues such as obesity, changing consumer lifestyles, increased investments in research and development of advanced insulin injection mechanisms, and the availability of safety pen devices and pen needles for optimal insulin delivery.
The key trends boosting the market growth are the rising incidences of diabetes and the increasing geriatric population.
The major regions in the industry are North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
The significant product types include drugs and delivery device.
The major types of the product include insulin analogs and biosimilars, and delivery device.
The significant brands include NovoRapid/Novolog, Humalog, Insuman, Humulin, Lantus, Actrapid, Insulatard, and Mixtard, and others.
The different delivery devices include pens, syringes, pen needles, and others.
The major applications of the product include Type 1 and Type 2.
The major players in the industry are Novo Nordisk A/S, Biocon Limited, Sanofi S.A., Pfizer Inc., Eli Lilly and Company, and others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999$2999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999$5999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER